Completed PHASE2 INTERVENTIONAL 5-arm NCT01822340

Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients (HM10560A)

A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)

Sponsor: Hanmi Pharmaceutical Company Limited

Conditions Adult Growth Hormone Deficiency

Interventions Genotropin HM10560A

Updated 5 times since 2017 Last updated: Feb 17, 2016 Started: Oct 31, 2011 Primary completion: Jun 30, 2015 Completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01822340, this PHASE2 trial focuses on Adult Growth Hormone Deficiency and remains completed. Sponsored by Hanmi Pharmaceutical Company Limited, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanmi Pharmaceutical Company Limited

Data source: Hanmi Pharmaceutical Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Budapest, Hungary